Exchange: NASDAQ·Updated 07:58 PM EDT
SNY logo

SNYSanofi-Aventis

$41.63
$1.03
(2.41%)
Today
Closed $41.63
$0.02
(0.05%)
After Hours
EarningsJul 30
Mkt Cap$100.09B
Vol4.52M
News
all
press releases
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Zacks
News Placeholder
More News
News Placeholder
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Zacks
News Placeholder
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.read more...
Benzinga
News Placeholder
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
Zacks
News Placeholder
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims (UPDATED)
EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany and France.read more...
Benzinga
News Placeholder
Deutsche Bank Cuts PT on Sanofi (SNY) - Here's Why
Deutsche Bank Cuts PT on Sanofi (SNY) - Here's Why...
Yahoo! Finance: News
News Placeholder
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Zacks
News Placeholder
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Zacks
News Placeholder
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.
Zacks
News Placeholder
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
Zacks
<
1
2
...
>

Advertisement|Remove ads.